THE TRANSITION TOWARS PERSONALIZED MEDICINE
2011
2014
TIME LINE
Van Cutsem E. J Clin Oncol. 2009
Data 2009 Data 2014
KRAS-MUT
Any RAS-MUT
KRAS Ex2
N = 397
RAS 2-4
N = 460
Δ
15%
Overall Survival (QT+Cmab)
KRAS-WT E2: 23,5 m Any RAS-WT: 28,4 m
KRAS-MT E2: 17,5 m Any RAS-MT: 16,4 m
Van Cutsem E. J Clin Oncol. 2015
31
